Back to Search Start Over

Development and Evaluation of a Clinical Decision Support System to Improve Medication Safety

Authors :
Carmen Guadalupe Rodríguez-González
Belén Marzal-Alfaro
Jose Luis De la Rosa-Triviño
Irene Iglesias-Peinado
Sara Ibáñez-García
Maria Luisa Martin-Barbero
Vicente Escudero-Vilaplana
Ana Herranz-Alonso
María Sanjurjo Sáez
Source :
Appl Clin Inform
Publication Year :
2019
Publisher :
Georg Thieme Verlag KG, 2019.

Abstract

Background Clinical decision support systems (CDSSs) are a good strategy for preventing medication errors and reducing the incidence and severity of adverse drug events (ADEs). However, these systems are not very effective and are subject to multiple limitations that prevent their implementation in clinical practice. Objectives The objective of this study was to evaluate the effectiveness of an advanced CDSS, HIGEA, which generates alerts based on predefined clinical rules to identify patients at risk of an ADE. Methods A multidisciplinary team defined the system and the clinical rules focusing on medication errors commonly encountered in clinical practice. Four intervention programs were defined: (1) dose adjustment in renal impairment; (2) adjustment of anticoagulation/antiplatelet therapy; (3) detection of biochemical/hematologic toxicities; and (4) therapeutic drug monitoring. We performed a 6-month observational prospective study to analyze the effectiveness of these clinical rules by calculating the positive predictive value (PPV). Results The team defined 211 clinical rules. During the study period, HIGEA generated 1,086 alerts (8.9 alerts per working day), which were reviewed by pharmacists. Fifty-one percent (554/1,086) of alerts generated an intervention to prevent a possible ADE; of these, 66% (368/554) required a documented modification to therapy owing to a real prescription error intercepted. The intervention program that induced the highest number of modifications to therapy was the dose adjustment in renal impairment program (PPV = 0.51), followed by the adjustment of anticoagulation/antiplatelet therapy program (PPV = 0.24). The percentage of accepted interventions was similar in surgical units (68%), medical units (67%), and critical care units (63%). Conclusion Our study offers evidence that HIGEA is highly effective in preventing potential ADEs at the prescription stage.

Details

ISSN :
18690327
Volume :
10
Database :
OpenAIRE
Journal :
Applied Clinical Informatics
Accession number :
edsair.doi.dedup.....f6af68e272cbd82d5c7635f77ce9a38c
Full Text :
https://doi.org/10.1055/s-0039-1693426